

ZUNVEYL® Dosing and Titration

Start at 5 mg, Increase to 10 mg

- The recommended starting dosage is 5 mg orally twice daily with or without food.
- Increase to initial maintenance dosage of 10 mg twice daily after a minimum of 4 weeks based on clinical response and tolerability.
- Dosage may be increased to the maximum recommended dosage of 15 mg twice a day after a minimum of 4 weeks at 10 mg twice daily.
- If therapy has been interrupted for more than three days, the patient should be restarted at the lowest dosage and the dosage escalated to the current dose.



ZUNVEYL Recommended Dosing Schedule



Please see Dosage and Administration section of the full Prescribing Information for complete information on dosing.

BID=twice daily

INDICATION AND USAGE

ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

SELECT SAFETY INFORMATION

CONTRAINDICATIONS

ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.

ADVERSE REACTIONS

The most common adverse reactions with galantamine tablets ($\geq 5\%$) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.

For more information, please see reverse for additional Safety Information and full Prescribing Information available from your representative.

- ZUNVEYL can be taken with or without food and should not be taken with alcohol.¹
- Ensure adequate fluid intake during treatment.¹
- **Tablets should be swallowed whole; do not split, crush or chew.¹**
- **Renal impairment:** Should not exceed 10 mg twice daily for creatinine clearance 9 to 59 mL/min; use in patients with creatinine clearance less than 9 mL/min is not recommended.¹
- **Hepatic impairment:** In patients with moderate hepatic impairment the dosage should generally not exceed 10 mg twice daily (20 mg/day). The use of ZUNVEYL in patients with severe hepatic impairment is not recommended.¹


ZUNVEYL
(benzgalantamine)
DELAYED RELEASE TABLETS
5 mg | 10 mg | 15 mg

How to Order ZUNVEYL

ZUNVEYL can be ordered using your facility's prescription order forms or EHR.

- To order ZUNVEYL with titration, add specific instructions such as *ZUNVEYL 5mg/tablet BID x 28 days, then increase to 10 mg/tablet BID.*
- Including “DAW,” “Dispense as Written,” or “Medically Necessary” helps ensure that residents get the medication that was prescribed.

ZUNVEYL Order Example

PHYSICIAN'S TELEPHONE ORDERS	Facility Name		Address		# of Doses Taken From EDK/Backup
	Patient Name		Admission Number	Room Number	
	Date Ordered	Time Ordered	Date DC	MEDICATION/Order Schedule	INDICATION-DX
				Dose & Form Route	
				<i>ZUNVEYL 5 mg/tablet BID x 28 days, then increase to 10 mg/tablet BID</i>	G30.9 [†]

* Other diagnostic codes include G30.0, G30.1, G30.8, F00.0, F00.1, F00.2, and F00.9.

[†] Nothing in this document is intended to serve as reimbursement advice. The decision about which code to report must be made by the provider/physician considering the clinical facts, circumstances, and applicable coding rules.

BID=twice daily; DC=discontinued; DX=diagnosis; EDK=emergency drug kit; EHR=electronic health record.

NOTE: To add titration schedule to a ZUNVEYL order in an EHR system, select *ZUNVEYL Oral Tablet Delayed Released* option (no specific strength), so both the starting and maintenance doses can be added at the same time.

SELECT SAFETY INFORMATION (CONTINUED)

USE IN SPECIFIC POPULATIONS

HEPATIC IMPAIRMENT:

Should not exceed 10 mg twice daily for moderate hepatic impairment; use in patients with severe hepatic impairment is not recommended.

RENAL IMPAIRMENT:

Should not exceed 10 mg twice daily for creatinine clearance 9 to 59 mL/min; use in patients with creatinine clearance less than 9 mL/min is not recommended.

Please see accompanying full Prescribing Information from your representative.

REFERENCES:

1. ZUNVEYL. Package insert. Alpha Cognition; Vancouver, B.C. Canada; 2024.



ZUNVEYL is a registered trademark and ALPHA COGNITION, ALPHA COGNITION logo, and the ZUNVEYL logo are trademarks of Alpha Cognition protected in Canada, the U.S. and in other countries. All other trademarks are the property of their respective owners.

©2025 Alpha Cognition. All rights reserved. US-ZUNV-00029 V3

Scan the QR code or visit
Zunveyl.com to unveil more



ZUNVEYL
(benzgalantamine)
DELAYED RELEASE TABLETS
5 mg | 10 mg | 15 mg